Intravenous Labetalol Versus Hydralazine in Preeclampsia

Tanta University

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Preeclampsia Severe

Treatments: Drug: Labetalol Injection; Drug: HydrALAZINE Injection

Study type: Interventional

Funder types: Other

Identifiers

NCT06360601

36264PR589/3/24

Details and patient eligibility

About

We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome

Enrollment: 40 estimated patients

Sex: Female

Ages: 25 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient with clinical diagnosis of sever preeclampsia

Exclusion criteria

Patient with history of previous intracranial lesion Patient with history of heart disease/allergy to drug Patient with history of arrhythmia/anticoagulation Any craniotemporal lesion

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

40 participants in 2 patient groups

Labetalol group

Active Comparator group

Treatment:

Drug: Labetalol Injection

Hydralazine group

Active Comparator group

Treatment:

Drug: HydrALAZINE Injection